Does Cigna Cover Weight Loss Treatment in Delaware? A 2026 Guide

Last updated: July 23, 2026

If you have Cigna health insurance in Delaware and you’re exploring weight loss treatment, understanding your formulary options, prior authorization rules, and prescription requirements may help you navigate costs and coverage. This guide covers what Cigna members in Delaware may expect in 2026, including the key difference between Cigna’s pharmacy benefit manager (Express Scripts) and other Delaware insurers that use CVS/Caremark.

Key facts for Cigna Delaware members (2026):

• PBM: Express Scripts (ESI)
• Zepbound (tirzepatide for weight loss): NOT removed from ESI formulary. Maintained at Tier 3. 4 with PA. Key differentiator vs. plans using CVS/Caremark, which removed Zepbound July 1, 2025 and plans reinstatement October 1, 2026.
• Wegovy (semaglutide for weight loss): Tier 3. 4 specialty, PA required
• Phentermine/Qsymia: Schedule IV controlled substances. Delaware EPCS required for all prescriptions
• GLP-1s and Contrave: Non-scheduled. Delaware EPCS does not apply
• State parity law (§ 3343): Applies to mental health and substance use disorders only. Does NOT govern weight loss treatment coverage
• Medicare GLP-1 Bridge: Not applicable for Cigna commercial members (available only through Humana Medicare Advantage)

Weight loss treatment through telehealth may be available to Delaware Cigna members through providers like Klarity Health, which connects patients with 2,000+ licensed providers across specialties. See if you may qualify for weight loss treatment through Klarity Health.

Cigna and Weight Loss Coverage in Delaware: The ESI Difference

One of the most important factors for Delaware Cigna members exploring GLP-1 medications in 2026 is Cigna’s use of Express Scripts (ESI) as its pharmacy benefit manager. This matters because ESI made a different formulary decision than CVS/Caremark regarding Zepbound (tirzepatide, FDA-approved for chronic weight management).

Zepbound: ESI Never Removed It

CVS/Caremark removed Zepbound from its commercial formulary on July 1, 2025, affecting Aetna and other CVS/Caremark-administered plans. CVS/Caremark has announced reinstatement effective October 1, 2026. During this gap, Aetna DE members have had limited or no formulary coverage for Zepbound.

Express Scripts (Cigna’s PBM) took a different approach: Zepbound was retained on ESI’s commercial formulary at Tier 3. 4, with prior authorization required. This means Cigna Delaware members who meet PA criteria have had continued formulary access to Zepbound throughout this period. A meaningful advantage for patients who qualify.

Cigna Delaware Weight Loss Formulary (Express Scripts, 2026)

Disclaimer: Formulary tiers and PA requirements vary by specific Cigna plan. Always verify your benefits with Cigna (1-800-244-6224) or ESI (1-800-835-3784) before initiating treatment.

Delaware EPCS Requirements for Weight Loss Medications

Delaware requires Electronic Prescribing of Controlled Substances (EPCS) for Schedule II through Schedule V medications under Delaware Admin Code Title 24 § 1700. For weight loss medications, this applies narrowly:

Practical note: GLP-1 medications (Wegovy, Zepbound, Saxenda) are not controlled substances. Delaware’s EPCS requirement does not apply to them. Telehealth providers can prescribe these through standard electronic prescribing systems, meaning there is no controlled substance barrier for GLP-1 prescribing in Delaware.

Does Delaware Parity Law (§ 3343) Apply to Weight Loss?

Delaware’s mental health parity law, Del. Code Ann. tit. 18, § 3343, requires insurers to cover mental health and substance use disorder services no more restrictively than comparable medical or surgical benefits. This is a meaningful protection for conditions like ADHD, anxiety, and depression.

However, § 3343 does NOT apply to weight loss treatment. Obesity and weight management are not classified as mental health or substance use disorders under § 3343. Weight loss coverage is governed instead by:

• The specific plan benefit design (Cigna’s summary plan description)
• ACA Essential Health Benefits (EHB) rules, which do not mandate weight loss drug coverage for all plans
• Express Scripts formulary decisions
• Employer plan documents for employer-sponsored plans

This means a denial of weight loss medication coverage by Cigna cannot be appealed using Delaware’s § 3343 parity framework. Appeals must proceed through standard plan appeal procedures and, for ERISA employer plans, through DOL EBSA.

Prior Authorization: What Cigna and ESI Require for GLP-1s

Prior authorization is required for Wegovy and Zepbound under most Cigna commercial plans administered by ESI. Common PA criteria include:

1. BMI threshold: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
2. Diet and lifestyle documentation: Evidence of participation in or referral to a structured diet/lifestyle intervention program
3. Trial of prior therapies: Some ESI plans require documented trial of other weight loss interventions before approving specialty GLP-1s
4. Prescriber specialty: Some plans require prescribing by a primary care physician, endocrinologist, or obesity medicine specialist
5. Continued use criteria: Renewal PA typically requires documented weight loss response (often ≥5% body weight at 3. 6 months) and ongoing lifestyle program participation

How to Start the PA Process

1. Obtain a prescription from your provider specifying the FDA-approved weight loss indication and relevant BMI/comorbidity documentation
2. Your provider or Klarity Health submits a PA request to ESI
3. ESI reviews within the plan’s standard timeframe (typically 3. 5 business days; urgent requests 24. 72 hours)
4. If approved, PA is generally valid for 12 months with renewal required
5. If denied, request the specific clinical criteria used for the denial. This is your basis for appeal

What Is Not Covered: Cigna Weight Loss Exclusions to Know

• Ozempic and Mounjaro for weight loss: ESI covers these only for their FDA-approved diabetes indications. Off-label prescribing for weight loss is typically excluded from commercial formulary coverage
• Compounded GLP-1s: Compounded semaglutide and tirzepatide are not covered by Cigna commercial plans. FDA shortage status for brand-name GLP-1s has been resolved as of 2025, and compounding restrictions under FDA enforcement are now active
• Weight loss surgery: Bariatric surgery coverage depends on specific plan benefits. Separate from outpatient medication coverage
• Meal replacement programs: Generally not covered under Cigna commercial pharmacy benefits

Medicare GLP-1 Bridge: Not Available to Commercial Cigna Members

As of July 1, 2026, CMS launched a Medicare GLP-1 Bridge program providing eligible Medicare Advantage (Part D) members access to Wegovy, Zepbound, and Foundayo at $50/month. This program was initiated through participating Medicare Advantage plans and applies to qualifying members of those plans.

This program does not apply to Cigna commercial members. It is specific to Medicare Advantage beneficiaries. Commercial Cigna members must rely on the standard ESI formulary and PA process described above. If you are a Cigna Medicare Advantage member rather than a commercial member, contact Cigna at 1-800-244-6224 to ask about Medicare Part D GLP-1 coverage under your specific plan.

Manufacturer Savings Programs

Even with commercial Cigna coverage, out-of-pocket costs for specialty GLP-1 medications can be significant. Manufacturer savings programs may reduce costs for eligible commercially insured patients:

• Novo Nordisk (Wegovy): Wegovy WeightLoss360 savings card. Eligible commercially insured patients may pay as low as $0/month (terms and income limits apply)
• Eli Lilly (Zepbound): Lilly Cares Foundation programs and Zepbound savings card for commercially insured patients
• Important: These savings programs generally cannot be used for Medicare or Medicaid beneficiaries

How to Verify Your Cigna Weight Loss Benefits

1. Log in to myCigna.com and search for Wegovy, Zepbound, or phentermine under your plan’s drug formulary
2. Call Cigna member services at 1-800-244-6224 and ask: “Is Wegovy/Zepbound covered under my plan? What are the PA criteria?”
3. Call Express Scripts at 1-800-835-3784 to verify formulary tier and PA requirements directly
4. Ask your provider to run a benefits verification (BV) before submitting a PA. Many telehealth practices including Klarity Health do this as part of intake
5. Request Cigna’s Summary of Benefits and Coverage (SBC) and any separate prescription drug formulary documents if information online is unclear

What to Do If Cigna Denies Your Weight Loss Medication

Step 1. Request the Explanation of Benefits (EOB) and denial reason

Cigna is required to provide a written denial with the specific clinical criteria it applied. Request this in writing.

Step 2. Internal appeal

Submit a formal internal appeal with supporting clinical documentation: provider notes, BMI measurements, comorbidity diagnoses, and any documentation of prior lifestyle interventions.

Step 3. Peer-to-peer review

Your prescriber can request a peer-to-peer call with ESI’s reviewing pharmacist or physician. This is often effective for specialty medications when clinical documentation is strong.

Step 4. External appeal via Delaware DOI

If Cigna upholds the denial after internal appeal, you may request an independent external review through the Delaware Department of Insurance at 1-302-674-7300. Delaware law provides the right to external review for adverse coverage decisions.

Step 5. ERISA appeal (employer-sponsored plans)

If your Cigna plan is an employer-sponsored ERISA plan, the Department of Labor Employee Benefits Security Administration (EBSA) at 1-866-444-3272 can assist with ERISA claims and appeals. Note: § 3343 parity appeals do not apply to weight loss denials. Use standard ERISA/DOL pathways instead.

Cigna vs. Other Delaware Insurers: Weight Loss Coverage Comparison

The practical advantage for Cigna DE members: unlike Aetna members who faced a Zepbound coverage gap from July 2025 through September 2026, Cigna/ESI members have had continuous formulary access to Zepbound throughout this period. If you were switched off Zepbound or had claims denied due to formulary removal, that would not apply to your Cigna plan. ESI did not remove it.

Telehealth and Weight Loss Treatment in Delaware

GLP-1 medications like Wegovy and Zepbound can be prescribed via telehealth in Delaware. Because these medications are not controlled substances, Delaware’s EPCS mandate does not create a barrier for telehealth prescribing. Providers can use standard e-prescribing systems to send GLP-1 prescriptions to your preferred pharmacy.

Phentermine and Qsymia are controlled substances (Schedule IV), which means:

• Delaware EPCS is required for all prescriptions
• Federal Ryan Haight Act restrictions apply. An in-person evaluation may be required before telehealth prescribing depending on the provider’s state registration and DEA registration
• Some telehealth providers do not prescribe controlled substances; confirm prescribing scope before scheduling

Klarity Health’s network of 2,000+ licensed providers includes practitioners experienced in weight loss treatment. See if you may qualify for a weight loss evaluation through Klarity Health.

Frequently Asked Questions

Does Cigna cover Zepbound in Delaware?

Zepbound (tirzepatide for weight loss) is maintained on the Express Scripts formulary at Tier 3. 4. Prior authorization is typically required. Unlike Aetna/CVS Caremark plans, ESI did not remove Zepbound from its commercial formulary. Coverage may vary by your specific Cigna plan, so verifying benefits with Cigna (1-800-244-6224) or ESI (1-800-835-3784) before initiating treatment is recommended.

Does Cigna cover Wegovy in Delaware?

Wegovy (semaglutide 2.4 mg for weight loss) is covered by many Cigna commercial plans through ESI at Tier 3. 4 specialty, with prior authorization required. PA criteria typically include BMI ≥30 or BMI ≥27 with a weight-related comorbidity and documentation of lifestyle interventions. Coverage may vary by specific plan.

Is Ozempic covered for weight loss under Cigna?

Generally no. ESI covers Ozempic (semaglutide 0.5. 2 mg) only for its FDA-approved diabetes indication. Using Ozempic off-label for weight loss is typically not covered under Cigna commercial pharmacy benefits. Wegovy (same molecule, higher dose, weight loss indication) is the appropriate formulary pathway for weight loss.

Does Delaware parity law protect weight loss coverage?

No. Delaware’s mental health parity law (Del. Code Ann. tit. 18, § 3343) applies to mental health and substance use disorder benefits. Not weight loss. Weight loss treatment coverage is determined by plan design and ESI formulary decisions. Parity appeal arguments do not apply to weight loss medication denials.

Do I need EPCS for a Wegovy or Zepbound prescription in Delaware?

No. Wegovy and Zepbound are not controlled substances. Delaware’s EPCS requirement (Schedule II. V) does not apply. Standard e-prescribing is sufficient, which means there is no EPCS-related barrier for telehealth GLP-1 prescribing in Delaware.

What if Cigna denies my weight loss medication PA request?

Request the written denial with specific clinical criteria, then submit an internal appeal with full clinical documentation (BMI measurements, comorbidity records, lifestyle program documentation). Your provider can request a peer-to-peer review with ESI’s clinical reviewer. If the denial is upheld, file an external appeal with the Delaware Department of Insurance at 1-302-674-7300. For employer-sponsored plans, DOL EBSA (1-866-444-3272) can assist with ERISA-related claims.

Contact Information

• Cigna Member Services: 1-800-244-6224 | myCigna.com
• Express Scripts (ESI): 1-800-835-3784 | express-scripts.com
• Delaware Department of Insurance: 1-302-674-7300 | delawareinsurance.gov
• DOL EBSA (ERISA plans): 1-866-444-3272 | dol.gov/agencies/ebsa
• CMS (Medicare/Medicaid): 1-800-633-4227 | cms.gov

Disclaimer: This guide is for informational purposes only and does not constitute legal, medical, or insurance advice. Coverage terms, formulary tiers, and prior authorization criteria may vary by specific Cigna plan, employer, and plan year. Always verify your benefits directly with Cigna and Express Scripts before initiating treatment. Coverage described reflects general ESI commercial formulary practices as of July 2026 and is subject to change.